Top

Published in:

Open Access 01-12-2008 | Case report

A dramatic, objective antiandrogen withdrawal response: case report and review of the literature

Authors: Yiu-Keung Lau, Manpreet K Chadha, Alan Litwin, Donald L Trump

Published in: Journal of Hematology & Oncology | Issue 1/2008

Abstract

Antiandrogen withdrawal response is an increasingly recognized entity in patients with metastatic prostate cancer. To our knowledge, there have been no reports describing a durable radiologic improvement along with prostate-specific antigen (PSA) with discontinuation of the antiandrogen agent bicalutamide. We report a case in which a dramatic decline of serum PSA levels associated with a dramatic improvement in radiologic disease was achieved with bicalutamide discontinuation.

Available only for authorised users

American Cancer Society, Cancer Facts and Figures 2007. 2007, Altanta, American Cancer Society

Kelly WK, Slovin S, Scher HI: Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am. 1997, 24: 421-31. 10.1016/S0094-0143(05)70389-X.CrossRefPubMed

Paul R, Breul J: Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf. 2000, 23: 381-90. 10.2165/00002018-200023050-00003.CrossRefPubMed

Miyamoto H, Rahman MM, Chang C: Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem. 2004, 91: 3-12. 10.1002/jcb.10757.CrossRefPubMed

Kelly WK, Scher HI: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993, 149: 607-9.PubMed

Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993, 11: 1566-72.PubMed

Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol. 1993, 150: 908-13.PubMed

Herrada J, Dieringer P, Logothetis CJ: Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol. 1996, 155: 620-3. 10.1016/S0022-5347(01)66468-1.CrossRefPubMed

Small EJ, Srinivas S: The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995, 76: 1428-34. 10.1002/1097-0142(19951015)76:8<1428::AID-CNCR2820760820>3.0.CO;2-T.CrossRefPubMed

10.

Small EJ, Carroll PR: Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology. 1994, 43: 408-10. 10.1016/0090-4295(94)90092-2.CrossRefPubMed

11.

Schellhammer PF, Venner P, Haas GP, Small E, Nieh P, Seabaugh D, Patterson A, Klein E, Wajsman Z, Furr B: Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol. 1997, 157: 1731-5. 10.1016/S0022-5347(01)64846-8.CrossRefPubMed

12.

Gomella LG, Ismail M, Nathan FE: Antiandrogen withdrawal syndrome with nilutamide. J Urol. 1997, 157: 1366-10.1016/S0022-5347(01)64984-X.CrossRefPubMed

13.

Huan SD, Gerridzen RG, Yau JC, Stewart DJ: Antiandrogen withdrawal syndrome with nilutamide. Urology. 1997, 49: 632-4. 10.1016/S0090-4295(96)00558-4.CrossRefPubMed

14.

Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Preston Gable P, Frank M, Torti FM, Ellen Kaplan E, et al: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004, 22: 1025-33. 10.1200/JCO.2004.06.037.CrossRefPubMed

15.

Scher HI, Zhang Z, Cohen L, Kelly WK: Hormonally relapsed prostatic cancer: Lessons from the flutamide withdrawal syndrome. Advances in Urology. 1995, 8: 61-95.

16.

Figg WD, Sartor O, Cooper MR, Thibault A, Bergan R, Dawson N, Reed E, Myers C: Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med. 1995, 98: 412-4. 10.1016/S0002-9343(99)80323-4.CrossRefPubMed

17.

Collinson MP, Daniel F, Tyrrell CJ, Teasdale C: Response of carcinoma of the prostate to withdrawal of flutamide. Br J Urol. 1993, 72: 662-3.CrossRefPubMed

18.

Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linhan WM, Myers CE: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst. 1994, 86: 222-7. 10.1093/jnci/86.3.222.CrossRefPubMed

19.

Nieh PT: Withdrawal phenomenon with the antiandrogen casodex. J Urol. 1995, 153: 1070-2. 10.1016/S0022-5347(01)67644-4.CrossRefPubMed

20.

Wilding G, Chen M, Gelmann EP: Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate. 1989, 14: 103-15. 10.1002/pros.2990140204.CrossRefPubMed

21.

Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate. 1996, 29: 153-8. 10.1002/1097-0045(199609)29:3<153::AID-PROS2990290303>3.0.CO;2-5.CrossRefPubMed

22.

Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990, 173: 534-40. 10.1016/S0006-291X(05)80067-1.CrossRefPubMed

23.

Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, Crusius K, Egner U, Donner P: Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem. 2002, 45: 1439-46. 10.1021/jm011072j.CrossRefPubMed

24.

Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995, 332: 1393-8. 10.1056/NEJM199505253322101.CrossRefPubMed

25.

Taplin ME, Rajeshkumar B, Halabi S, Cary P, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, et al: Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003, 21: 2673-8. 10.1200/JCO.2003.11.102.CrossRefPubMed

26.

Lee YF, Lin WJ, Huang J, Messing EM, Chan Fl, Wilding G, Chawnshang C: Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res. 2002, 62: 6039-44.PubMed

27.

Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004, 10: 33-9. 10.1038/nm972.CrossRefPubMed

28.

Zhu P, Baek SH, Bourk EM, Ohgi K, Garcia-Bassets I, Sanjo H, Akira S, Kotol P, Glass C, Rosenfeld M: Macrophage/Cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell. 2006, 124: 615-29. 10.1016/j.cell.2005.12.032.CrossRefPubMed

Title: A dramatic, objective antiandrogen withdrawal response: case report and review of the literature
Authors: Yiu-Keung Lau
Manpreet K Chadha
Alan Litwin
Donald L Trump
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2008
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-1-21

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Possible immunotherapeutic potentiation with D-Fraction in prostate cancer cells

Novel therapies in genitourinary cancer: an update

Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts

Left sided inferior vena cava duplication and venous thromboembolism: case report and review of literature

Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML)

Current status of haploidentical stem cell transplantation for leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer